Logo
x

Search

Subscribe Now

IASO Bio

IASO Bio Reports the US FDA’s IND Approval of Equecabtagene Autoleucel for Two New Autoimmune Diseases

IASO Bio Reports the US FDA’s IND Approval of Equecabtagene Autoleucel for Two New Autoimmune Diseases

  • August 12, 2024
IASO Bio and Innovent’s CT103A/ IBI326 Receive the US FDA’s Orphan Drug Designation for Multiple Myeloma

IASO Bio and Innovent’s CT103A/ IBI326 Receive the US FDA’s Orphan Drug Designation for Multiple Myeloma

  • February 14, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.